Venture&Growth Archives - Gilde Healthcare

Menu
Menu
Home

latest news
Venture&Growth

Gilde Healthcare company Amphista Therapeutics enters a up to $1.0 billion strategic collaboration with Merck

Amphista and Merck will collaborate to leverage Amphista’s proprietary EclipsysTM TPD platform and generate novel protein degrading therapeutics in oncology and immunology Collaboration includes up to €39 million ($44 million) in combined upfront and R&D funding payments for an initial three programs Amphista will potentially receive up to €893.5 million ($1.0 billion) in total payments across three programs plus mid-single digit...
May 4, 2022

Gilde Healthcare company Amphista Therapeutics enters a up to $1.25 billion strategic collaboration with Bristol Myers Squibb

test Amphista and Bristol Myers Squibb to collaborate and leverage Amphista’s proprietary Eclipsys™ targeted protein degradation platform to develop novel protein degrading therapeutics Collaboration includes an upfront payment of $30 million, the potential for up to $1.25 billion in performance-based milestone payments and payments for a limited expansion of the collaboration, as well as royalties on […]

Gilde Healthcare company ADCendo appoints Dominik Mumberg, PHD, as Chief Scientific Officer

test Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immuno-oncology and small molecules Adcendo building a world class team of experienced biotech & pharma executives and renowned leaders in the ADC field Adcendo ApS (“Adcendo”), a therapeutics company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers, today […]

Gilde Healthcare anchors $103.5 million public offering by Affimed

Gilde announces that it acted as anchor investor in an upsized $103.5 million public offering by German immune-oncology company Affimed N.V. (Nasdaq: AFMD) (“Affimed”). As a result, Gilde’s ownership exceeds 5% of the outstanding share capital of Affimed. “We are excited to team up with the excellent...

Noema Pharma announces first patient dosed in phase 2b study of NOE-101 in trigeminal neuralgia

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system diseases, today announces the dosing of its first patient in its Phase 2b clinical trial of the mGluR5 inihibitor NOE-101 in trigeminal neuralgia (TN). LibraTN is a multi-center, 24-week, prospective, double-blind, randomized-withdrawal, placebo-controlled study to...

Gilde Healthcare co-leads $104 million financing in Nalu Medical

Nalu Medical, Inc. (“Nalu”), a private medtech company focused on providing minimally invasive solutions for treating chronic pain, announced today the completion of a $104 Million equity financing. The round was led by new investors Gilde Healthcare and MVM Partners. Also participating in this round were new investors Pura Vida Investments and...

Gilde Healthcare invests in Eur 50M series A round of Spanish Gene Therapy company SpliceBio

SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced the completion of an oversubscribed €50 million series A financing. The financing was co-led by UCB Ventures and existing shareholder Ysios Capital and joined by new investors New Enterprise Associates (NEA), Gilde...

Gilde Healthcare portfolio company Withings acquires leading health and fitness app 8fit

Withings, the leader in at-home connected health, today announces the acquisition of 8fit, a worldwide health, fitness, and wellness app with more than 40 million downloads. Available in 6 languages, 8fit offers effcient workouts, customized meal plans, and self-care guidance to users. Its capabilities further strengthen Withings’...

Gilde Healthcare Portfolio Company Big Health Adds Former FDA Deputy Commissioner Anand Shah to Its Board of Directors

Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced that it has added former Food and Drug Administration (FDA) Deputy Commissioner for Medical and Scientific Affairs Dr. Anand Shah to its Board of Directors. This key addition follows Big...
Loading...
These were all messages
ebb22415da